EGF-A peptides: A promising strategy for PCSK9 inhibition

Atherosclerosis. 2020 Jan:292:204-206. doi: 10.1016/j.atherosclerosis.2019.11.010. Epub 2019 Nov 19.

Authors

Bertrand Cariou¹, Wieneke Dijk²

Affiliations

¹ L'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France. Electronic address: bertrand.cariou@univ-nantes.fr.
² L'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France.

PMID: 31784031
DOI: 10.1016/j.atherosclerosis.2019.11.010

No abstract available

Keywords: Hypercholesterolemia; LDLR; Lipid-lowering drugs; PCSK9; Small peptides.

Publication types

Editorial
Comment

MeSH terms

Epidermal Growth Factor*
Proprotein Convertase 9*
Proprotein Convertases
Receptors, LDL

Substances

Receptors, LDL
Epidermal Growth Factor
PCSK9 protein, human
Proprotein Convertase 9
Proprotein Convertases